FOXO3a Reverses the Cisplatin Resistance in Ovarian Cancer

Ovarian cancer is one of the most serious disease in female reproductive system. Platinum is the first-line drug for the treatment of ovarian cancer, while the resistance of platinum drug in clinical hindered the relief ovarian cancer. Our previous study found that decreased FOXO3a might be a poor prognosis in human ovarian cancer. In this research, we study whether FOXO3a was involved in the mechanism of platinum drug resistance.

https://www.arcmedres.com/article/S0188-4409(18)30130-9/fulltext?rss=yes

Source: Archives of Medical Research - April 28, 2018 Category: Research Authors: Mudan Lu, Xuan Chen, Jianping Xiao, Jingying Xiang, Lan Yang, Daozhen Chen Tags: Original Article Source Type: research